Acute meningococcaemia: Recent advances in management (with particular reference to children)

Anaesthesia and Intensive Care

Volumn 24, Issue 2, 1996, Pages 197-216

  Kennedy, N J ^a,b   Duncan, A W ^a  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Intensive care: septicaemia, shock, N. meningitidis, meningococcus

Indexed keywords

ANTIBIOTIC AGENT; ANTITHROMBIN III; CEPHALOSPORIN; HEPARIN; MENINGOCOCCUS VACCINE; PENICILLIN G; PROSTACYCLIN; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOTTING DISORDER; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; EXTRACORPOREAL OXYGENATION; FULMINATING PURPURA; GANGRENE; HEMOFILTRATION; HUMAN; HYPERVENTILATION; IMMUNE RESPONSE; MENINGOCOCCEMIA; METABOLIC ACIDOSIS; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; REGIONAL ANESTHESIA; REVIEW; SCORING SYSTEM; SEPTIC SHOCK; SEPTICEMIA; SHOCK; VASCULAR ACCESS;

EID: 0029995283     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x9602400212     Document Type: Review

References (184)

1. Boslego JW, Tramont EC. Neisseria meningitidis. In: Gorbach SL, Bartlett JG, Blacklow NR, eds Infectious Diseases. Ch 214. WB Saunders Co. Philadelphia, Pennsylvania. 1992; 1452-1458.
2. Hart CA, Rogers TRF. Meningococcal Disease (Review). J Med Microbiol 1993; 39:3-25.
3. Patel MS, Merianos A, Hanna N, et al. Epidemic meningococcal meningitis in Central Australia, 1987-1991. Med J Aust 1993; 158:336-340.
4. Schlech WF III, Ward JI, Band JD, et al. Bacterial meningitis in the United States, 1978 through 1981. JAMA 1985; 253:1749-1754.
5. Peltola H, Kataja JM, Makela PH. Shift in the age distribution of meningococcal disease as a predictor of an epidemic? Lancet 1982; 2:595-597.
6. Achtman M, Kusecek B, Morelli G, et al. A comparison of the variable antigen expressed by Clone IV-1 and subgroup C of Neisseria Meningitidis Serogroup A. J Infect Dis 1992; 65:53-68.
7. Moore PS. Meningococcal meningitis in Sub-Saharan Africa: A model for the epidemic process. Clin Infect Dis 1992; 14:515-525.
8. Tubkin SD. Neisseria meningitidis bacteraemia. Pediatr Infect Dis J 1982; 1:37.
9. Ackerman AD. Infectious diseases of importance to the pediatric intensivist. In Ch 26. Textbook of Paediatric Intensive Care 1987. Williams and Wilkins, Baltimore.
10. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus I. The role of humoral antibodies. J Exp Med 1969; 129:1307-1326.
11. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus II. Development of natural immunity. J Exp Med 1969; 129:1327-1348.
12. Gold R, Lepow ML. Present state of polysaccharide vaccines in the prevention of meningococcal disease. Adv Pediatr 1976; 23:71-93.
13. Ellison RT III, Kohler PF, Curd JG, et al. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N Engl J Med 1983; 308:913-916.
14. DeVoe IW. The meningococcus and mechanisms of pathogenieity. Microbiol Rev 1982; 46:162.
15. Densen P. Interaction of complement with N.meningitidis and N. Gonorrhoea. Clin Microbiol Rev 1989; 2:S11.
16. Waage A, Brandtzaeg P, Halstenson A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333-338.
17. Brandtzaeg P, Mollnes TE, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160:58-65.
18. Brandtzaeg P, Kierulf P, Gaustad P et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease . J Infect Dis 1989; 159:195-204.
19. Schwartz B, Moore PS, Broome CV. Global epidemiology of meningococcal disease. Clin Microbiol Rev 1989; 2:5118-124.
20. Poolman JT, Lind I, Jonsdottir K, Froholm LO, et al. Meningococcal serotypes and serogroup B disease in Northwest Europe. Lancet 1986; 2:555-557.
21. Jones DM. Epidemiology of meningococcal infection in England and Wales. J Med Microbiol 1988; 26:165-168.
22. Harrison LH. The worldwide prevention of meningococcal infection. Still an elusive goal. JAMA 1995; 273(5):419-421.
23. Robinson P, Spelman D. Chemoprophylaxis against meningococcal infection. Matters arising. Med J Aust 1993; 159:138.
24. Frasch CE, Mocca LF. Strains of N.Meningitidis isolated from patients and their close contacts. Infect Immun 1982; 37:155-159.
25. Figen CAP, Kuijper EJ, Tija HG, et al. Complement deficiency predisposes for meningitis due to nongroupable meningococci and Neisseria related bacteria. Clin Infect Dis 1994; 18:780-784.
26. Moore PS, Harrison LH, Telzak EE, et al. Group A meningococcal carriage in travellers returning from Saudi Arabia. JAMA 1988; 260:2686-2689.
27. Cartwright KAV Influenza A and meningococcal disease. Lancet 1991; 338:554-557.
28. Greenwood BM, et al. Meningococcal disease and season in Sub-Saharan Africa. Lancet 1985; 2:829-830.
29. Stuart JM, Cartwright KAV, Robinson PM, et al. Effect of smoking on meningococcal carriage. Lancet 1989; 2:723-725.
30. Moore PS, Hierholzer J, DeWitt W, et al. Respiratory viruses and Mycoplasma as cofactors for Group A meningococcal meningitis. JAMA 1990; 264:1271-1275.
31. Bohm RC, Balcbalk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992: 101; 1644-1655.
32. Jafari HS, McCracken GH. Sepsis and septic shock: Review for clinicians. Pediatr Inf Dis J 1992; 11:739-749.
33. Saez-Llorens X, McCracken GH Jnr. Sepsis syndrome and septic shock in paediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 1993; 123:497-508.
34. Hayden WR. Sepsis Terminology in Paediatrics. J Pediatr 1994; 124:657-658.
35. Tesoro LJ, Selbst SM. Factors affecting outcome in meningococcal infections, AJDC 1991:145; 218-220.
36. Jones DM, Abbott JD. Meningococcal disease in England and Wales. In: Vedros MA (ed). Evolution of meningococcal disease, Vol 1 Publisher Boca Ratom, FL, CRC Press 198; pp 65-90.
37. Grossman M. Bacterial and viral infections. 1982. In Ch 13. Pediatrics. Prentice-Hall International Inc.
38. Thompson APJ, Marzouk O, Sills JA, et al. Meningococcal disease (Review). J Med Microbiol 1993; 39:3-25.
39. Gedde-Dahl TW, Hoiby EA, Schillinger A, Lystad A, Bovne K, An epidemiological clinical and microbiological follow-up study of incident meningococcal disease cases in Norway, winter 1981-82. Material and epidemiology in the MenOPP project. MIPH Ann 1983;6:155-168.
40. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus IV. Immunogenicity of Group A and Group C meningococcal polysaccharide in human volunteers. J Exp Med 1969; 1368-1384.
41. Keogh C, Fong Y, Marano MA et al. Identification of a novel TNFα from the livers of burned and infected rats. Arch Surg 1990; 125:79-85.42.
42. Danas P, Aimee R, Gysen P et al. TNF and IL-1 serum levels during severe sepsis in humans. Crit Care Med 17;975-978.
43. Hack CE et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-10.
44. Moldawer LL. Biology of pro-inflammatory cytokines and their antagonists. Crit Care Med 1994; 22(7):S 3-S-7.
45. Waage A, Halstensen A, Espevic T. Association between TNF in serum and fatal outcome in meningococcal disease. Lancet 1987 ; I:355-357.
46. Cerami A, Bentler B. The role of cachetin/TNFα in endotoxic shock and cachexia. Immunol Today 1988; 9:28-31.
47. Casey LC, Balk RA, Bone RC. Plasma cytokine levels correlate with survival in patients with the sepsis syndrome. Ann Int Med 1993;119:771-778.
48. Giradin E, Grau GE, Dyer JM, Roux-Lombard P, Lambert PH. TNFα and IL-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397-400.
49. Dinarello CA, Wolff SM. The role of interleukin 1 in disease. N Eng J Med 1993; 328: 49 106-113.
50. Suffredin AF. Current prospects for the treatment of clinical sepsis. Crit Care Med 1994; 22:512-518.
51. Granowitz EV, Santos AA, Poutsiaka DD et al. Production of interleukin 1 receptor antagonist during experimental endotoxaemia. Lancet 1991; 338:1423-1424.
52. Giradin E, Roux-Lombard P, Grau GE, et al. The J5 study group. Imbalance between TNFα and soluble TNFα receptor concentration in severe meningococcaemia. Immunology 1992; 76:20-23.
53. Villard J, Roux-Lombard P, Hugli A, Dayer JM. Could natural inhibitors of TNFα modify the course of fulminant meningococcaemia? Crit Care Med 1993; 23(9): 1396-1399.
54. Van Deuren, van der Ven-Jongekrijg, Demacher PNM et al. Differential expression of pro-inflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 1994;169:157-161.
55. Derkx B, Marchant A, Goldman M, et al. High levels of Il-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171(1):229-232.
56. Hazelzet JA, van der Voort E, Lindemann J et al. Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 1994; 20:371-374.
57. Pollack MM, Ruttiman UE, Getson PR et al. Paediatric risk of mortality score(PRISM). Crit Care Med 16:1110-1116.
58. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med 1990; 20:80-93.
59. Madden RM, Gill JC, Marlar RA. Protein C and Protein S levels in two patients with acquired purpura fulminans. Br J Haematol 1990; 75:112-117.
60. Francis RB et al. Semin Thromb Hemost 1990; 16:310-25.
61. Adcock DM, Hicks MJ. Dermatopathology of skin necrosis associated with purpura fulminans. Semin Thromb Hemost 1990; 16:83-92.
62. Suffradin A, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activator after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320:1165-1172.
63. Cupperman M, Inkelis SH, Saladino R. The role of heparin in prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 1994;13:867-783.
64. Beutler B, Grau GE. TNFα in the pathogenesis of infectious disease. Crit Care Med 1993; 25:S43-S45.
65. Gonda Y, Hirata S, Saitsh K. Antithrombotic effect of recombinant soluble thrombomodulin on endotoxin induced DIC in rats. Thromb Res 1993; 71(4):325-335.
66. Powars D, Larsen R, Johnson J et al. Epidemic meningococcaemia and purpura fulminans with induced Protein C deficiency. Clin Infect Dis 1993; 17:254-261.
67. Van der Poll T, Buller HR, ten Cate H et al. Activation of coagulation after administration of TNFα to normal subjects. New Engl J Med 1990;322:1622-1627.
68. Oltrud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection related to unfavourable prognosis. Thromb Haemost 1983; 49:5-7.
69. Conway EM, Bach R, Rosenberg RD. TNF enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53:231-241.
70. Van der Poll T, Leuin M, Buller HR et al. Fibrinolytic response to TNFα in healthy subjects. J Exp Med 1991; 174:729-33.
71. Lorente JA, Garcia-Frade IJ, Landin L et al. Time course of haemostatic abnormalities in sepsis and relation to outcome. Chest 1993; 103:1536.
72. Fourrier F, Chopin C, Goudemend J et al. Septic shock, multiorgan failure, and disseminated intravascular coagulation. Compared patterns of Antithrombin III, Protein C and Protein S deficiencies. Chest 1992; 101(3):816-823.
73. Leclerc F, Hazelzet J, Jude B et al. Protein C and S deficiency in severe infective purpura of children. A study of 40 cases. Intensive Care Med 1992; 18(4):202-205.
74. Fijnvandraat K, Derx B, Peters M et al. Coagulation activation and tissue necrosis in meningococcal septic shock. Severely reduced Protein C levels predict a high mortality. Thromb Haemost 1995; 73(1):15-20.
75. Pollack MM, Fields A, Ruttiman UE. Sequential cardiopulmonary variables of infants and children in septic shock. Crit Care Med 1984; 12:554-559.
76. Pollack MM, Fields A, Ruttiman UE. Distribution of cardiopulmonary variables in paediatric survivors and non survivors of septic shock. Crit Care Med 1985; 13:454-459.
77. Mar MF, et al. Haemodynamic study in meningococcal septic sock (review). Anales Espanoles De Pediatrica 1991; 11:21-25.
78. Gedde-Dahl TW, Bjark P, Hoiby EA, et al. Severity of meningococcal disease: Assessment by factors and scores and implications for management. Rev Inf Dis 1990; 12(6):973-990.
79. Mercier JC, Beaufils F, Hartmann JF, et al. Haemodynamic patterns of meningococcal shock in children. Crit Care Med. 1988; 16(1):27-33.
80. Busund R, Straume B, Revhaug A. Fatal Course in Severe Meningococcaemia. Clinical Predictors and Effective Transfusion Therapy. Crit Care Med 1993; 21:1699-1705.
81. Boucek MM, Boerth RC, Artman M et al. Myocardial dysfunction in children with acute meningococcaemia. J Pediatr 1984; 105:538.
82. Stiehm ER, Damrosch DS. Factors in the prognosis of meningococcal infection. J Pediatr 1966; 68:457-467.
83. Niklasson P, Lundbergh P, Strandeil T. Prognostic factors in meningococcal infection. Scand J Infect Dis 1971; 3:17-25.
84. Lewis LS. Prognostic factors in acute meningococcaemia. Arch Dis Child 1979; 54:44-48.
85. LeClerc F, Beuscart R, Guillois B, et al. Prognostic factors of severe infectious purpura in children. Intensive Care Med 1985;11:140-143.
86. Kahn A, Blum D. Factors for the prognosis of fulminating meningococcaemia. Clin Pediatr(Phil) 1978;17:680-687.
87. Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicaemia. Lancet 1987 ii:38.
88. Thomson APJ, Sills JA. Validation of the GMSPS:A 10 year retrospective survey. Crit Care Med 1991; 19(1):26-30.
89. StocklandT, Flaestad T, Gutteberg TJ. A clinical score for the prediction of outcome of patients with meningococcal infection. Acta Paediatr Scand 1985; S322:12.
90. Le Gall JR. Do we need a new severity score? 1991 Crit Care Med 19:857-858.
91. Shah A, Matthew DJ. GMSPS in meningococcal septicaemia Crit Care Med 1992; 20:1495.
92. Algren JT, Suresh L, Cutliff SA, et al. Predictors of outcome in acute meningococcal infection in children. Crit Care Med 1993; 21(3):447-452.
93. McManus ML, Churchwell KB. Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response with purpura. Crit Care Med 1993; 21(5):706-711.
94. Berron S, Vazquez JA. Increase in moderate penicillin resistance and serogroup C in meningococcal stains isolated in Spain. Is there a relationship? Clin Infect Dis 1994; 18:161-165.
95. Saez-Nieto JA, Lujan R, Berron S, et al. Epidemiology and molecular basis of penicillin-resistant Neisseria Meningitidis from Spain: a five year history (1985-89). Clin Infect Dis 1992; 14:394-402.
96. Meningococcal isolate surveillance; Australia 1994. CDI 1995; 19(12): 286-289.
97. Ziegler EJ, McCuthan JA, Fierer J et al. Treatment of Gram-negative bacteraemia and shock with human antiserum to a mutant E Coli. N Engl J Med 1982; 307:1225-1230.
98. Baumgartner JD, Glauser MP, McCuthan JA et al. Prevention of Gram- negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 1985, Vol 11:59-63.
99. Calandra T, Glauser MP, Schellekens J et al. Treatment of Gram-negative septic shock with human IgG antibody to Esherishia Coli J5. J Infect Dis 1988; 158:312-319..
100. J5 study group: Treatment of severe infectious purpura in children with human plasma from donors immunised with Esherishia Coli J5: a perspective double-blind study. J Infect Dis 1992; 165:695-701.
101. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324:429-436
102. McClosky RV, Straube RC, Sanders C, et al. Treatment of septic shock with HA-1A: a randomised double-blind placebo controlled trial. CHESS trial study group. Ann Int Med 1994; 121 (1):1-5.
103. French National Registry of HA-1A in septic shock. A cohort study of 600 patients. Arch Int Med 1994; 154(21):2484-2491.
104. Luce JM. Introduction of new technology in critical care practice. A history of H1-1A human monoclonal antibody against endotoxin. Crit Care Med 1993; 21:1233-1234.
105. Wester JPJ, Breumelhof R, Geers ABM. Monoclonal antibodies in the treatment of adult fulminant meningococcaemia. Euro J Med 1992; 1:372-373.
106. Syed SA, Taylor RH, Crean PM, Stewart RJ. Successful use of monoclonal anti-lipid A IGM in an infant with meningococcal septicaemia. Lancet 1992; 33:496.
107. Fisher CJ, Opal SM, Dhainaut JF, et al. Influence of anti tumour necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327.
108. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human TNFα in patients with sepsis syndrome. A randomised, controlled, double-blind, multicentre clinical trial. TNFα MAb sepsis study group. JAMA 1995; 273(12):934-941.
109. Jin H, Yang R, Marsters SA et al. Protection against rat endotoxic shock by P55 TNFα receptors immunoadhesin: comparisons with anti- TNFα monoclonal antibody. J Infect Dis 1994; 170(5):1323-1326.
110. Fisher CJ Jnr, Dhairait JF, Pribble JP et al. A study evaluating the efficacy of human recombinant interleukin 1 receptor antagonist (IL-1 RA) in the treatment of patients with sepsis syndrome. Preliminary results. Clin Intens Care 1993; 4:85.
111. Mustafa MM, Ramilo O, Mertsola J et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type B meningitis. J Infect Dis 1989; 160:818-825.
112. Tauber M, Khayam-Bushi H, Sande MA. Effects of ampicillin and corticosteroids on brain water content, CSF pressure and CSF lactate levels in experimental pneumococcal meningitis. J Infect Dis 1985; 151:528-533.
113. Odio et al. Beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 324(22):1524-1531.
114. McCracken GH Jnr, Label MH. Dexamethasone treatment for bacterial meningitis in infants and children. AJDC 1989; 143:287-289.
115. Havens PL, Wendelberger KJ, Hoffman GM et al. Corticosteroids in adjunctive therapy in bacterial meningitis. A meta analysis of clinical trials. AJDC 1989; 143:1051-1055.
116. Girgis NI, Farid Z, Michail IA et al. Dexamethasone treatment for bacterial meningitis in children and adults. Pediatr Infect Dis J 1989; 8:848-851.
117. Kennedy WA, Hoyt MJ, McCracken GH Jnr. The role of corticosteroid therapy in children with pneumococcal meningitis. AJDC 1991; 145:1374-1378.
118. Bhatt SM, Cabellos C, Nadol JB Jnr et al. The impact of dexamethasone on hearing loss in experimental pneumococcal meningitis. Pediatr Infect Dis J 1995; 14:93-96.
119. Syrogiannopoulos GA, Lourida AN, Theodoridou MC. Dexamethasone therapy for bacterial meningitis; 2 versus 4 day regimen. J Infect Dis 1994; 169:853-858.
120. Schaad UB, Lips U, Gnehm HE et al. Dexamethasone therapy for bacterial meningitis in children. Lancet 1993; 342:457-461.
121. The report of the committee on infectious diseases, American Academy of Paediatrics. 23rd edition. Elk Grove Village, IL; American Academy of Paediatrics 1994; 220-229, 323-326, 558-559.
122. The meningitis working party of the British paediatric immunology and infectious diseases group. Should we use dexamethasone in meningitis? Arch Dis Child 1992; 67:1398-1401.
123. Schein RMH, Sprung CL, Marcial E et al. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990; 18:259-263.
124. Wajchenberg B, Lerne CE, Tambascia M, et al. The adrenal response to exogenous adrenocorticotrophin in patients with infections due to Neisseria meningitis. J Infect Dis 1978 138(3); 387-391.
125. Beutiler B, Krochin N, Milsark IW et al. Control of cachectin (TNFα) synthesis: mechanisms of endotoxin resistance. Science 1986; 232:977-980.
126. Saez-Llorens X, Ramilo O, Mustafa MM et al. Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr 1990; 116:681-684.
127. Sprung C, Caralis PV, Marcial EH et al. The effects of high dose corticosteroids in patients with septic shock: a prospective controlled study. N Engl J Med 1984; 311:1137-1143.
128. Hoffman SL, Punjabi NH, Kumala S et al. Reduction of mortality in chloramphenicol treated severe typhoid fever by high dose dexamethasone. N Eng J Med 1984; 310:82-88.
129. Bone RC, Fisher CJ, Clemmer TP et al. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-658.
130. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317:659-65.
131. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotrophin and survival in septic shock. Lancet 1991; 337:582-583.
132. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995; 23:1294-1303.
133. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotrophin and survival in septic shock. Lancet 1991; 337:582-583.
134. Soni A, Pepper GN, Wyrwinski PM et al. Adrenal insufficiency occurring during septic shock: incidents, outcome, and relationship to peripheral cytokine levels. Am J Med 1995; 98:266-271.
135. Briegel J, Kellerman W, Forst H et al. Low dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clinical Investigator 1994; 72(10):782-787.
136. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin 6 activates the hypothalamic-pituitary-adrenal access in humans. J Clin Endocrinol Metab 1993; 77:1690-1694.
137. Taylor FB, Chang AR Jr, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of E.Coli infusion in the baboon. J Clin Invest 1987; 79:918-925.
138. Nardi M, Karpathin M. Prothrombin and Protein C in early childhood. Normal adult levels are not achieved until the fourth year of life. J Pediatr 1986; 117(5):843-845.
139. Dreyfus M, et al. Treatment of homozygous Protein C deficiency in neonatal purpura fulminans with purified Protein C concentrate. N Engl J Med 1991; 32:1565-1568
140. Rivad GE, Davies M, Farrell C. Treatment of purpura fulminans in meningococcaemia with Protein C concentrate. J Pediatr 1995; 126(4):646-652.
141. Gerson WT, Dickenson JT, Bovill EG. Severe acquired Protein C deficiency in purpura fulminans associated with DIC: treatment with Protein C concentrate. Pediatrics 1993; 91:418-420.
142. Pilcher L, Hruby E, Schwarz HP. Attenuation of the Schwartzman reaction rabbits by human activated protein C. (Abstract) Thromb Haemost 1991; 65:1205.
143. Bick RL, Ancypa D. Blood protein defects associated with thrombosis. Clinics in Laboratory Medicine II 1995; 14(1):125-163.
144. Fourrier F, Lestravel P, Chopin C, et al. Meningococcaemia and purpura fulminans in adults. Acute deficiencies of Protein C and S, and early treatment with AT III concentrate. Intens Care Med 1990; 16:121-124.
145. Fourrier F, Chopin C, Huart JJ, et al. Double blind placebo controlled trial of AT III concentrates in septic shock with DIC. Chest 1993; 104:882-888.
146. van Beek EJ, van der Mollen MA, ten Cate JW. AT III concentrate in the treatment of DIC: A retrospective follow up study. Netherlands J Med 1994; 45(5):205-210.
147. Emerson TE Jr. AT III replacement in animal models of acquired AT III deficiency. Blood Coag d Fibrinol 1994; S1:S37-45
148. Harper PL. The clinical use of Antithrombin III in septicaemia. BJHM 1994;52(11):571-573.
149. Cobcroft R, Henderson A. Meningococcal purpura fulminans treated with AT III concentrate: what is the optimal replacement therapy? Aust NZ J Med 1994; 24:575.
150. Haneburg B, Gutteberg TG, Moe PJ et al. Hepann for infants and children with meningococcaemia: results of a randomised therapeutic trial. NIPH Ann 1983; 6:43-47.
151. Kupperman M et al. The role of heparin in preventing extremity and digit necrosis in meningococcal purpura fulminans. Ped Infect Dis J 1994; 13:867-873.
152. Du Toit HJ, Coetzee AR, Chalton DO. Heparin treatment in thrombin induced DIC in the baboon. Crit Care Med 1991; 19:1195.
153. Sakuragawa N et al. Clinical evaluation of low molecular weight heparins on DIC, a multi centre cooperative double blind trial in comparison with heparin. Thromb Res 1993; 72(6):475-500.
154. Lantz M, Thysell H, Nilsson E, et al. On the binding of TNFα to heparin and the release of in vivo TNFα binding protein I by heparin. J Clin Invest 1991; 88:2026-2031.
155. Stewart FJ, McClure BJ, Mayne E. Successful treatment of purpura fulminans using epoprostenol. J Roy Soc Med 1991; 84:623.
156. Winrow AP. Successful treatment of purpura fulminans using epoprostenol. J Roy Soc Med 1991; 85:245.
157. Klein NJ, Heyderman RS, Levin M. Management of meningococcal infections. BJHM 1993; 50(1):42-49.
158. Keeley SR, Matthews NT, Buist M. Tissue plasminogen activator for gangrene in fulminant meningococcaemia. Lancet 1991; 337:1359.
159. Zenz W, Muntean W, Gallistl S, et al. Recombinant Tissue Plasminogen Activator treatment in two infants with fulminant meningococcaemia. Pediatrics 1995; 96:144-147.
160. Scharfman WB, Tillotson JR, Taft EG. Plasmapheresis for meningococcaemia with DIC. N Engl J Med 1970; 30:1277-1278.
161. Bjorvatn B, Bjerknaes L, Fadnes HO, et al. Meningococcal septicaemia treated with continuous plasmapheresis and leucopheresis or with blood exchange. BMJ 1984; 288:439-441.
162. Westerndorp RG, Brandt A, Thompson J, et al. Experiences with plasma and leucopheresis in meningococcal septicaemia. Intensive Care Med. 1990; 16:S102.
163. Drapkin MS, Wish JS, Gelfland JA, et al. Plasmapheresis for fulminant meningococcaemia. Pediatr Inf Dis J 1989; 8:399-400.
164. Gardlund B, Sjolin J, Nilsson A. Plasmapheresis in treatment of primary septic shock in humans. Scand J Inf Dis 1993; 25(6):757-761.
165. Van Deusen M, Santman FW, Van Dalin R, et al. Plasmapheresis and whole blood exchange in meningococcal sepsis. Clin infect Dis 1992; 15:424-430.
166. Schetz M, Gasthuisberg UZ. Removal of cytokines in septic patients using continuous veno venous haemodiafiltration [letter:comment]. Crit Care Med 1994; 22(4):715-716.
167. Reimainn PN, Mason PD. Plasmapheresis: Technique and complications. Intensive Care Med 1990; 16:3-10.
168. Pollack M. Editorial response. Blood exchange and plasmapheresis in septic shock. Clin Infect Dis 1992; 15:431-433.
169. Bellomo R, Tipping P, Boyce N. Continuous veno venous haemofiltration with dialysis removes cytokines from the circulation in septic patients. Crit Care Med 1993; 21:522-526.
170. Tonnesen E, Hansen MB, Holmdorf , et al. Cytokines in plasma and ultrafiltrate during continuous arteriovenous haemofiltration. Anaesth Intens Care 1993; 21:752-758.
171. Bellomo R, Tipping P, Boyce. Removal of cytokines in septic patients using continuous veno venous haemodiafiltration. Crit Care Med 1994; 22(4):719-721.
172. Best C, Walsh J, Sinclair J, Beattie J. Early haemodiafiltration in meningococcal septicaemia. Lancet 1996; 347:202.
173. Champion MP, Murdoch IA, Sajjanhar T, Marsh MJ. Extracorporeal membrane oxygenation in refractory shock in fulminant meningococcaemia. Lancet 1996:1-202.
174. Anderson CT, Berde CB, Sethna NF et al. Meningococcal purpura fulminans: Treatment of vascular insufficiency in a 2 year old with lumbar sympathetic blockade. Anesthesiology 1989; 21:463-464.
175. Tobias JD, Haun SE, Helfaer M, Nichols DG. Use of continuous caudal blockade to relieve lower extremity ischaemia caused by vasculitis in a child with meningococcaemia. J Pediatr 1989; 115:1019-1021.
176. Herrera R, Hobar C, Ginsburg C. Surgical intervention for the complications of meningococcal-induced purpura fulminans. Pediatr Inf Dis J 1994; 13:734-737.
177. Hamdy RC, Babyn PS, Krajbich JI. Use of bone scan in management of patients with peripheral gangrene due to fulminant meningococcaemia. J Pediatr Orthopaed 1993; 13:447-451.
178. Hart CA, Cuevas LE. Chemoprophylaxis of meningococcal disease. J Med Microbiol 1993; 39:3-25.
179. The meningococcal surveillance group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976; 134:201-204.
180. Schwartz B, Al-Tabaigi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eliminating pharyngeal carriage of Group A N.meningitidis. Lancet 1988; I:1239-1242.
181. Abadi FJ, Yakubu DA, Pennington TH. Antimicrobial susceptibility of penicillin-sensitive and penicillin-resistant meningococci. J Antimicrob Chemother 1995; 35:687-690.
182. Gaunt PN, Lambert BE. Single dose Ciprofloxacin for the eradication of pharyngeal carriage of N.meningitidis. J Antimicrobial Chemother 1988; 21:489-496.
183. Frasch CE. Vaccines for the prevention of meningococcal disease. Clin Microbiol Rev 1989; 2:3134-138.
184. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. 1991 Lancet; 338:1093-1096.